Northern India Herald

TCM Lianhua Qingwen Capsule obtained registration approval in Uganda

 Breaking News
  • No posts were found

TCM Lianhua Qingwen Capsule obtained registration approval in Uganda

September 24
17:46 2020

Yiling Pharmaceutical Co., Ltd. (SHE: 002603) announced on Wednesday that it has received the registration approval issued by the National Drug Authority (NDA) of Uganda, indicating its product Lianhua Qingwen Capsule has been registered as Herbal Medicine in the country.

As a leading product of Yiling Pharmaceutical Co., Ltd., Lianhua Qingwen products are mainly used for the treatment of cold, flu-related diseases. In 2020, Lianhua Qingwen Capsule has been listed as a recommended medicine for the epidemic in the Diagnosis and Treatment Scheme of Novel Coronavirus Pneumonia (Versions #4-#8), issued by China’s national authorities. In April, 2020, the National Medical Products Administration of China approved that a new indication for “mild and common COVID-19” was added to Lianhua Qingwen Capsule on the basis of its originally approved indications.

Lianhua Qingwen has been widely used in hospitals designated for taking in and treating COVID-19 patients during the outbreak in China. The results of a prospective, randomized, controlled, and multi-center clinical study on treating COVID-19 with the TCM Lianhua Qingwen Capsules, which Academicians Zhong Nanshan, Li Lanjuan, and Zhang Boli and other experts worked on together with over 20 hospitals, were published in Phytomedicine, the journal with a high impact factor in the field of international herbal medicine. It’s found in the study in terms of clinical use that Lianhua Qingwen proved to be both safe and effective in treating COVID-19 in conjunction with conventional therapy as it could significantly relieve clinical symptoms of COVID-19 such as fever, debilitation, and cough, greatly improve pulmonary lesions, shorten the duration of symptoms, and increase the clinical recovery rate.

As of now, Lianhua Qingwen Capsule has been approved in nearly 20 countries and regions including Brazil, Philippines, Romania and Thailand. In Kuwait, the medicine has been for the first time granted permission in countries other than China to treat symptoms caused by mild and moderate cases of COVID-19.

Media Contact
Company Name: Yiling Pharmaceutical
Contact Person: Mia
Email: Send Email
Phone: +86-311-85901712
Country: China
Website: http://en.yiling.cn/

Related Articles